PAR 5.00% 19.0¢ paradigm biopharmaceuticals limited..

Ann: PAR Expanded Access IND Cleared by US FDA, page-11

  1. 1,041 Posts.
    lightbulb Created with Sketch. 31

    There isn’t any published data on PPS, other than a 2005 paper which reported the benefits of PPS over placebo. But if you dig in and read the results closely, it’s not overly compelling, but reports some benefits over control.

    The data that has been released to date is certainly promising, but also has its limitations. Like you said, lack of long term follow up is one - likely because results over placebo are not significant beyond 6 months to a year. Would love them to also report their effect sizes, and also the number of patients lost to follow up. These patients lost to follow up are typically considered treatment failures. 45% of PPS patients in the other study in 05 were lost to follow up. However the treatment dosage and frequency has changed since then.

    That being said, 6 months relief is likely better than visvosupplementation and corticosteroid. It’s also shown safety and efficacy, plenty of anecdotal results which is the same, if not better than other injectable treatments. Exercise and weight loss is still the number 1 treatment for OA as a first line treatment, but for those resistant to this, hopefully PPS proves to be a good adjunct / second line treatment. Better than an early TKR/THR anyway!

    Cupping and needling is absolutely useless for OA.
    Last edited by pist87: 10/09/19
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.